Gilead’s Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.

Health
By BY KATIE THOMAS from NYT Health https://ift.tt/34BnUum
via IFTTT your-feed-science, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Remdesivir (Drug), Research, Company Reports Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.

Comments

Post a Comment

Popular posts from this blog

Should the Autism Spectrum Be Split Apart?

Image
Health By Azeen Ghorayshi from NYT Health https://ift.tt/ZX2NkH3 via IFTTT Autism, Intellectual Disabilities, Asperger's Syndrome, Special Education, Mental Health and Disorders, Children and Childhood, United States Politics and Government, Medicine and Health Families of people with severe autism say the repeated expansion of the diagnosis pushed them to the sidelines. A new focus on the disorder has opened the way for them to argue their cause.
Read more

The Jarring Contradiction at the Heart of Kennedy’s Agenda

Image
Health By Benjamin Mueller and Dani Blum from NYT Health https://ift.tt/glFoDjr via IFTTT United States Politics and Government, Diet and Nutrition, Regulation and Deregulation of Industry, Food, Hazardous and Toxic Substances, Chemicals, Vaccination and Immunization, Rumors and Misinformation, Pesticides, Agriculture and Farming, Drugs (Pharmaceuticals), Food Contamination and Poisoning, Environment The health secretary has begun a full-on assault against vaccines but has taken a more restrained approach to pesticides and unhealthy foods, also MAHA priorities.
Read more